A new trading day began on Monday, with Immunome Inc (NASDAQ: IMNM) stock price down -5.28% from the previous day of trading, before settling in for the closing price of $10.60. IMNM’s price has ranged from $8.97 to $30.96 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 17.82%. With a float of $51.30 million, this company’s outstanding shares have now reached $60.42 million.
Let’s look at the performance matrix of the company that is accounted for 55 employees. In terms of profitability, gross margin is 88.22%, operating margin of -3134.4%, and the pretax margin is -3014.59%.
Immunome Inc (IMNM) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Immunome Inc is 17.80%, while institutional ownership is 81.92%. The most recent insider transaction that took place on Nov 21 ’24, was worth 630,263. In this transaction President and CEO of this company bought 66,057 shares at a rate of $9.54, taking the stock ownership to the 485,693 shares. Before that another transaction happened on Nov 22 ’24, when Company’s President and CEO bought 33,943 for $9.78, making the entire transaction worth $331,918. This insider now owns 519,636 shares in total.
Immunome Inc (IMNM) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.69 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 17.82% per share during the next fiscal year.
Immunome Inc (NASDAQ: IMNM) Trading Performance Indicators
Here are Immunome Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.17. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 61.86.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.12, a number that is poised to hit -0.67 in the next quarter and is forecasted to reach -3.11 in one year’s time.
Technical Analysis of Immunome Inc (IMNM)
Immunome Inc (NASDAQ: IMNM) saw its 5-day average volume 0.64 million, a negative change from its year-to-date volume of 0.64 million. As of the previous 9 days, the stock’s Stochastic %D was 33.39%. Additionally, its Average True Range was 0.76.
During the past 100 days, Immunome Inc’s (IMNM) raw stochastic average was set at 13.79%, which indicates a significant decrease from 30.36% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.61% in the past 14 days, which was lower than the 70.99% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.76, while its 200-day Moving Average is $13.97. Nevertheless, the first resistance level for the watch stands at $10.56 in the near term. At $11.09, the stock is likely to face the second major resistance level. The third major resistance level sits at $11.69. If the price goes on to break the first support level at $9.44, it is likely to go to the next support level at $8.84. Assuming the price breaks the second support level, the third support level stands at $8.31.
Immunome Inc (NASDAQ: IMNM) Key Stats
With a market capitalization of 626.67 million, the company has a total of 62,417K Shares Outstanding. Currently, annual sales are 14,020 K while annual income is -106,810 K. The company’s previous quarter sales were 2,910 K while its latest quarter income was -47,100 K.
